Agilent Technologies, Inc. Expected to Post Q3 2023 Earnings of $1.44 Per Share (NYSE:A)

Agilent Technologies, Inc. (NYSE:AGet Rating) – Research analysts at Jefferies Financial Group upped their Q3 2023 EPS estimates for Agilent Technologies in a research note issued to investors on Tuesday, November 22nd. Jefferies Financial Group analyst B. Couillard now anticipates that the medical research company will post earnings of $1.44 per share for the quarter, up from their prior forecast of $1.41. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.64 per share. Jefferies Financial Group also issued estimates for Agilent Technologies’ Q4 2023 earnings at $1.68 EPS and FY2023 earnings at $5.65 EPS.

Agilent Technologies (NYSE:AGet Rating) last posted its quarterly earnings data on Monday, November 21st. The medical research company reported $1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.14. Agilent Technologies had a net margin of 18.31% and a return on equity of 30.31%. The business had revenue of $1.85 billion during the quarter, compared to analysts’ expectations of $1.76 billion. During the same period last year, the firm posted $1.21 earnings per share. The business’s revenue was up 11.4% on a year-over-year basis.

A number of other brokerages also recently commented on A. Cowen increased their price objective on Agilent Technologies from $160.00 to $168.00 in a research report on Tuesday. Evercore ISI increased their price target on Agilent Technologies from $140.00 to $155.00 in a research report on Tuesday. Cowen lifted their price target on Agilent Technologies from $160.00 to $168.00 in a research note on Tuesday. Robert W. Baird upped their price objective on shares of Agilent Technologies from $160.00 to $170.00 in a research note on Tuesday. Finally, Credit Suisse Group initiated coverage on shares of Agilent Technologies in a research report on Wednesday, August 24th. They issued an “outperform” rating and a $165.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Agilent Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $157.00.

Agilent Technologies Stock Down 1.0 %

A stock opened at $155.35 on Wednesday. The firm has a market cap of $45.99 billion, a PE ratio of 37.25, a P/E/G ratio of 2.78 and a beta of 1.06. Agilent Technologies has a 12 month low of $112.52 and a 12 month high of $162.62. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.03 and a quick ratio of 1.41. The firm has a 50 day simple moving average of $133.99 and a 200 day simple moving average of $128.48.

Agilent Technologies Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 25th. Investors of record on Tuesday, January 3rd will be given a dividend of $0.225 per share. The ex-dividend date of this dividend is Friday, December 30th. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.21. This represents a $0.90 dividend on an annualized basis and a yield of 0.58%. Agilent Technologies’s dividend payout ratio (DPR) is 20.14%.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, VP Padraig Mcdonnell sold 2,506 shares of the business’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $134.33, for a total value of $336,630.98. Following the sale, the vice president now owns 15,320 shares of the company’s stock, valued at approximately $2,057,935.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Agilent Technologies news, VP Padraig Mcdonnell sold 2,506 shares of the stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $134.33, for a total transaction of $336,630.98. Following the completion of the transaction, the vice president now directly owns 15,320 shares in the company, valued at $2,057,935.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael R. Mcmullen sold 6,775 shares of Agilent Technologies stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $130.11, for a total value of $881,495.25. Following the completion of the transaction, the chief executive officer now directly owns 191,358 shares of the company’s stock, valued at $24,897,589.38. The disclosure for this sale can be found here. Insiders have sold 174,326 shares of company stock worth $26,474,537 over the last three months.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AIA Group Ltd grew its position in Agilent Technologies by 39.6% in the first quarter. AIA Group Ltd now owns 4,961 shares of the medical research company’s stock valued at $656,000 after purchasing an additional 1,408 shares in the last quarter. First Bank & Trust raised its holdings in shares of Agilent Technologies by 19.1% in the 2nd quarter. First Bank & Trust now owns 924 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 148 shares during the period. Associated Banc Corp lifted its stake in Agilent Technologies by 19.5% in the 1st quarter. Associated Banc Corp now owns 3,053 shares of the medical research company’s stock valued at $404,000 after purchasing an additional 499 shares during the last quarter. National Bank of Canada FI grew its holdings in Agilent Technologies by 1.3% during the first quarter. National Bank of Canada FI now owns 48,219 shares of the medical research company’s stock worth $6,242,000 after purchasing an additional 600 shares during the period. Finally, American Trust raised its stake in Agilent Technologies by 195.7% in the first quarter. American Trust now owns 4,581 shares of the medical research company’s stock valued at $606,000 after buying an additional 3,032 shares during the period.

About Agilent Technologies

(Get Rating)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.

Featured Articles

Earnings History and Estimates for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.